国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

更新于 12月8日

輝瑞制藥-China Strategy Consultant-上海

5-8萬(wàn)
  • 北京東城區(qū)
  • 5-10年
  • 本科
  • 全職
  • 招1人

雇員點(diǎn)評(píng)標(biāo)簽

  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 工作環(huán)境好
  • 人際關(guān)系好
  • 氛圍活躍
  • 實(shí)力大公司

職位描述

藥企
Brief Introduction of Pfizer China
Pfizer began its operations in China in the 1980’s and has become the No. 1 pharmaceutical company in China by achieving incredible growth in a challenging environment. China’s strategic value to Pfizer is not only in its huge commercial potential, but also as an increasingly important source of innovation in new drug assets and digital / internet-based health care. However, PBG China is facing significant challenges in the next 3-5 years, namely, VBP exposure for its matured products, and relatively lean innovative inline and pipeline portfolio. Business strategy is key to not only overcome the headwinds of VBP but also, more importantly, fully catch the tailwinds and transform the China business to an innovative-focused business and regain the No.1 leadership position in China.
Role overview
This China Strategy AD / SM position is a key role reporting to China Strategy Head under China Strategy team. The China Strategy team oversees Pfizer China and BU strategy development, working closely with China Regional President and all BUs / Functions in Pfizer China, as well as with the Pfizer regional /ICO / Global functions. The China Strategy AD/SM will closely work with China Strategy Head to help drive Pfizer China Strategy development and transform Pfizer China to an innovative-focused business through identifying and assessing external and internal key trends, exploring and capturing new opportunities, implementing endorsed strategies, and innovating the commercial model.
Many of the projects the Strategy team works on are to address ICO leadership team, China President level questions, involving global and local stakeholders across multiple functions. The stakeholders whom this role is managing are senior leaders either from HQ or in China. The strategic projects often have business impact for short term (next 1-2 years) and longer term (next 3-5 years). Besides, this role needs to work closely with China Leadership Team (CLT) to develop BU strategies and drive strategic projects to capture the strategic opportunities that will enable China business to leapfrog and remove hurdles that will hinders success of China business transformation.
One of the key metrics for evaluating the success of this role and the team is in the endorsement and execution of these strategies and buy-up proposals by global and local cross-functional working teams, by the China leadership team.
Role key responsibilities
The China Strategy AD/SM role is pivotal in supporting China Strategy Head to develop top-notch strategies and driving execution excellence – Typical projects are complex and challenging in nature, with high visibility in front of the China and global leadership. They include, but are not limited to, the following:

Pfizer China Strategy: develop holistic and long-term growth strategies to propel Pfizer China to achieve the growth aspiration and regain the leadership position under the transformational healthcare changes in China

Portfolio strategy: Develop strategy, direction, and priorities to evolve the current Pfizer China portfolio from a LOE dominated one to an innovative-product-focused one

BU strategy: Pfizer China has transformed its organization structure and established new franchises (BUs). Work closely with BU GMs/Franchise Heads to define BU growth aspiration, strategy, innovate GTM model unique to each BU’s development stage in China and define growth roadmap for implementation

Go-to-Market Transformation: The China environment has been evolving quickly in the last few years, with the rising influence of stakeholders beyond HCPs (such as patients, hospital management, medical associations, provincial and city governments, digital healthcare companies etc.). This role also needs to work very closely with Sales, Marketing, Access, Medical, Strategic Innovation to identify and enhance current GTM model, and pilot execution

Transformation Management Office (TMO): Critical to
Role expectations
In order to deliver on the above key responsibilities on a regular basis, the China Strategy AD/SM is expected to meet the following standards and excel in the processes below:

Strategic thinking mindset, project management and exceptional execution: Under guidance from China Strategy Head, this role will directly manage and execute multiple high-priority projects through opportunity assessment, business valuation, implementation planning. Ensure high deliverable quality, with professionalism, timeliness, and meeting global and local leadership expectations. Continuously engage with senior leaders to align overall direction, outputs, and future implications / next steps

China leadership team & cross-functional engagement, alignment and resources management: Able to effectively manage communication and build alignment on strategic priorities and implementation. Smoothly navigate cross-function communication, inputs gathering and alignment

Potential to be seen as a functional expert: This China Strategy AD/SM shall have a good understanding on China healthcare and pharmaceutical macro environment, challenges and opportunities, and able to derive a deeper and robust understanding of critical growth drivers for Pfizer China
Qualifications

4-8 years of functional experience in corporate strategy, management consulting, business operations, or strategic marketing related functions

Relevant healthcare consulting, pharmaceutical / biotech industry experiences, with in-depth knowledge about China pharmaceutical market

Highly strategic mindset and strong ability to connect the dots

Outstanding quantitative and analytical skills, including solid analytics, ability to build a compelling story, strategic recommendations, and detailed strategic plans

Superb ability to engage senior leaders and cross-functional colleagues and build alignment to deliver results in a matrix organization. This includes to advice and influence senior leaders both in China and globally.

Track record of success and impact in business managed or projects delivered. Must have experience of developing, executing on winning business proposals, with concrete value identified by senior management.

People management skill & track records of maintaining high-performing team required, either in a solid reporting structure, or in a virtual reporting structure.

Top-notch skills required – leadership, communication, ability to influence, strategic thinking, project management, problem solving, business acumen, innovativeness and creativity, analytical skills, interpersonal skills, teamwork, risk-taking, and flexibility operating in ambiguous and changing environment.

Bachelor / Master degree qualification in Strategy, Finance, Marketing or health-related disciplines; MBA-related experience is preferred

Excellent both English and Mandarin Chinese communications (working professional plus)
Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.
Bus Dev & Strategic Planning

工作地點(diǎn)

北京東城區(qū)五礦廣場(chǎng)-B座

職位發(fā)布者

王先生/區(qū)域招聘及入職交付

昨日活躍
立即溝通
公司Logo輝瑞投資有限公司
輝瑞公司(Pfizer Inc.)創(chuàng)建于1849年,總部位于美國(guó)紐約,是一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。輝瑞的使命是“為患者帶來(lái)改變其生活的突破創(chuàng)新”。在輝瑞,我們通過(guò)科學(xué)和全球資源為人們提供治療方案,以延長(zhǎng)其生命,顯著改善其生活。在醫(yī)療衛(wèi)生產(chǎn)品的探索、研發(fā)和生產(chǎn)過(guò)程中,輝瑞始終致力于奉行嚴(yán)格的質(zhì)量、安全和價(jià)值標(biāo)準(zhǔn)。我們?cè)谌虻漠a(chǎn)品組合包括創(chuàng)新藥品和疫苗。每天,輝瑞在發(fā)達(dá)和新興市場(chǎng)的員工都在推進(jìn)人類健康,推動(dòng)疾病的預(yù)防、治療和治愈,以應(yīng)對(duì)挑戰(zhàn)我們這個(gè)時(shí)代的頑疾。輝瑞還與醫(yī)療衛(wèi)生服務(wù)方、政府和社區(qū)合作,支持并促進(jìn)世界各地的人們能夠獲得更為可靠和可承付的醫(yī)療衛(wèi)生服務(wù)。這與輝瑞作為一家全球卓越的創(chuàng)新生物制藥公司的責(zé)任是一致的。170余年來(lái),輝瑞一直致力于為所有依賴我們的人帶來(lái)改變。輝瑞于1989年進(jìn)入中國(guó)市場(chǎng)。扎根中國(guó)30余年,輝瑞已成為在華主要的外資制藥公司之一。2021年是輝瑞新征程的開始。迄今已有170余年歷史的輝瑞正在邁入全新時(shí)代,成為一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。目前輝瑞在中國(guó)業(yè)務(wù)覆蓋全國(guó)300余個(gè)城市,累計(jì)投資超過(guò)15億美元,并設(shè)立了1家先進(jìn)的生產(chǎn)設(shè)施,2個(gè)研發(fā)中心(分別位于上海張江高科技園區(qū)和武漢光谷),在華有近7,000名員工分布于業(yè)務(wù)、研發(fā)和生產(chǎn)等領(lǐng)域。輝瑞在華上市了五大領(lǐng)域的高品質(zhì)創(chuàng)新產(chǎn)品,包括腫瘤、疫苗、抗感染、炎癥與免疫、罕見病等多個(gè)領(lǐng)域的處方藥和疫苗,強(qiáng)大完善的產(chǎn)品線旨在滿足生命各階段的健康需求。
公司主頁(yè)